Table 1 Correlations between SATB1 expression, clinicopathologic features and MGMT promoter methylation in 70 cases of glioma
From: Upregulation of SATB1 is associated with the development and progression of glioma
| Clinicopathologic variables | n | SATB1 expression | X 2 | P-value | |
|---|---|---|---|---|---|
| Negative | Positive | ||||
| All cases | 70 | 26 | 44 | ||
| Age (years) | 1.004 | 0.446 | |||
| <45 | 27 | 12 | 15 | ||
| 45 | 43 | 14 | 29 | ||
| Gender | 0.388 | 0.566 | |||
| Male | 54 | 19 | 35 | ||
| Female | 16 | 7 | 9 | ||
| Tumor size (cm) | 0.227 | 0.795 | |||
| <3 | 24 | 8 | 16 | ||
| 3 | 46 | 18 | 28 | ||
| Tumor locus | 0.946 | 0.393 | |||
| Supratentorial | 53 | 18 | 35 | ||
| Infratentorial | 17 | 8 | 9 | ||
| Pathological grade | 6.119 | 0.025 | |||
| Low grade I-II | 35 | 18 | 17 | ||
| High grade III-IV | 35 | 8 | 27 | ||
| MGMT promoter | 25.150 | 0.000 | |||
| Unmethylation | 45 | 7 | 38 | ||
| Methylation | 25 | 19 | 6 | ||